In the KATHERINE trial2, improved DFS was observed with adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab in patients with HER2+ breast cancer who had residual disease after neoadjuvant HER2-directed chemotherapy regimens. This evidence concerns the gene ERBB2 and breast cancer.